At the Food and Drug Administration, the physician and venture investor promoted policies focused on innovating approaches to population health, opioids, chronic disease, AI and precision medicine. Despite the concerns of some that his close ties with the pharmaceutical industry offered the potential for “unprecedented financial entanglements with the industries he would regulate as FDA commissioner,” others were hopeful that his energy and enthusiasm would help “accelerate the discovery, development and delivery of new cures and treatments” to address some of the most pressing problems in the U.S. healthcare industry.In his resignation letter, Gottlieb cited his work on e-cigarettes and youth vaping, the opioid crisis, access to generic drugs, efforts to “reduce the burden of chronic disease through better information and diets” and other population health imperatives. He also pointed to recent approvals for new gene therapies and other precision medicine tools.

Source: Click here